

Special Issue

Advances in Brain Tumors: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editors

This Special Issue focuses on the biological mechanisms driving brain tumor initiation, progression and treatment resistance, with an emphasis on translational opportunities for patient care. We welcome original research and high-quality reviews addressing tumor pathophysiology, molecular and metabolic reprogramming, tumor microenvironment and immune evasion and clinically relevant biomarkers. Particular interest is given to innovative therapeutic approaches, including targeted therapies, immunotherapy, metabolic interventions, drug delivery strategies and multimodal combinations. Contributions integrating advanced neuroimaging, radiomics, artificial intelligence and intraoperative tools to support precision neuro-oncology are also encouraged, aiming to bridge mechanistic insights with improved diagnosis, stratification and personalized treatment.

Guest Editors

Dr. Giovanni Pennisi

Department of Neurosurgery, San Giovanni Addolorata Hospital, Rome, Italy

Dr. Placido Bruzzaniti

Neurosurgery Division of "Spaziani" Hospital, Frosinone, Italy and Sapienza University of Rome, 00185 Rome, Italy

Deadline for manuscript submissions

28 February 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/283943

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).